# OnCo record padeliporfin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/padeliporfin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "padeliporfin" ;
  schema:name "Padeliporfin"@en ;
  schema:alternateName "WST11"@en, "Padeliporfin di-potassium"@en, "Vascular-targeted photodynamic therapy (VTP)"@en, "Tookad" ;
  schema:description "Tookad is a light-activated drug for men with low-risk prostate cancer in one side of the prostate. It is infused and then switched on with laser fibres placed in the gland, destroying the cancer-bearing tissue as an alternative to watchful waiting."@en ;
  schema:url <https://onco.cc/drugs/padeliporfin/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Padeliporfin> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/tookad>, <https://doi.org/10.1016/S1470-2045(16)30661-1>, <https://www.nice.org.uk/guidance/ta546> ;
  onco:status "approved" ;
  onco:tag "ema-list" ;
  onco:modality "Intravenous photosensitiser for vascular-targeted photodynamic therapy" ;
  onco:approval "EU 2017: Unilateral, low-risk, previously untreated prostate adenocarcinoma in men with life expectancy of at least 10 years (Tookad VTP)" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/active-surveillance/> ;
  onco:companies <https://onco.cc/companies/steba-biotech/> ;
  onco:terms <https://onco.cc/terms/active-surveillance-term/>, <https://onco.cc/terms/prostate-focal-therapy/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/nct01310894/>, <https://onco.cc/trials/nct01875393/>, <https://onco.cc/trials/nct03315754/> .